Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Zika virus set to spread across Americas, spurring vaccine hunt

Mon, 25th Jan 2016 17:14

* Mosquito-borne virus linked to birth defects in Brazil

* Brazil's Butantan Institute aims to develop vaccine

* GSK and Sanofi reviewing vaccine possibilities

* More research needed into potential sexual transmission (Adds comment from GlaxoSmithKline and Sanofi, graphic link)

By Tom Miles and Ben Hirschler

GENEVA/LONDON, Jan 25 (Reuters) - The mosquito-borne Zikavirus, which has been linked to brain damage in thousands ofbabies in Brazil, is likely to spread to all countries in theAmericas except for Canada and Chile, the World HealthOrganization said on Monday.

Zika transmission has not yet been reported in thecontinental United States, although a woman who fell ill withthe virus in Brazil later gave birth to a brain-damaged baby inHawaii.

Brazil's Health Ministry said in November that Zika waslinked to a foetal deformation known as microcephaly, in whichinfants are born with smaller-than-usual brains.

Brazil has reported 3,893 suspected cases of microcephaly,the WHO said last Friday, over 30 times more than in any yearsince 2010 and equivalent to 1-2 percent of all newborns in thestate of Pernambuco, one of the worst-hit areas.

The Zika outbreak comes hard on the heels of the Ebolaepidemic in West Africa, demonstrating once again howlittle-understood diseases can rapidly emerge as global threats.

"We've got no drugs and we've got no vaccines. It's a caseof deja vu because that's exactly what we were saying withEbola," said Trudie Lang, a professor of global health at theUniversity of Oxford. "It's really important to develop avaccine as quickly as possible."

Large drugmakers' investment in tropical disease vaccineswith uncertain commercial prospects has so far been patchy,prompting health experts to call for a new system of incentivesfollowing the Ebola experience.

"We need to have some kind of a plan that makes (companies)feel there is a sustainable solution and not just a one-shotdeal over and over again," Francis Collins, director of the U.S.National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute is currently leadingthe research charge on Zika and said last week it planned todevelop a vaccine "in record time", although its director warnedthis was still likely to take three to five years.

British drugmaker GlaxoSmithKline said on Monday itwas studying the feasibility of using its vaccine technology onZika, while France's Sanofi said it was reviewingpossibilities.

RIO CONCERNS

The virus was first found in a monkey in the Zika forestnear Lake Victoria, Uganda, in 1947, and has historicallyoccurred in parts of Africa, Southeast Asia and the PacificIslands. But there is little scientific data on it and it isunclear why it might be causing microcephaly in Brazil.

Laura Rodrigues of the London School of Hygiene and TropicalMedicine said it was possible the disease could be evolving.

If the epidemic was still going on in August, when Brazil isdue to host the Olympic Games in Rio de Janeiro, then pregnantwomen should either stay away or be obsessive about covering upagainst mosquito bites, she said.

The WHO advised pregnant women planning to travel to areaswhere Zika is circulating to consult a healthcare providerbefore travelling and on return.

The clinical symptoms of Zika are usually mild and oftensimilar to dengue, a fever which is transmitted by the sameAedes aegypti mosquito, leading to fears that Zika will spreadinto all parts of the world where dengue is commonplace.

More than one-third of the world's population lives in areasat risk of dengue infection, in a band stretching throughAfrica, India, Southeast Asia and Latin America.

Zika's rapid spread, to 21 countries and territories in theAmericas since May 2015, is due to the prevalence of Aedesaegypti and a lack of immunity among the population, the WHOsaid in a statement.

RISK TO GIRLS

Like rubella, which also causes mild symptoms but can leadto birth defects, health experts believe a vaccine is needed toprotect girls before they reach child-bearing age.

Evidence about other transmission routes, apart frommosquito bites, is limited.

"Zika has been isolated in human semen, and one case ofpossible person-to-person sexual transmission has beendescribed. However, more evidence is needed to confirm whethersexual contact is a means of Zika transmission," the WHO said.

While a causal link between Zika and microcephaly has notyet been definitively proven, WHO Director-General Margaret Chansaid the circumstantial evidence was "suggestive and extremelyworrisome".

In addition to finding a vaccine and potential drugs tofight Zika, some scientists are also planning to take the fightto the mosquitoes that carry the disease.

Oxitec, the UK subsidiary of U.S. synthetic biology companyIntrexon, hopes to deploy a self-limiting geneticallymodified strain of insects to compete with normal Aedes aegypti.

Oxitec says its proprietary OX513A mosquito succeeded inreducing wild larvae of the Aedes mosquito by 82 percent in anarea of Brazil where 25 million of the transgenic insects werereleased between April and November. Authorities reported a bigdrop in dengue cases in the area.

(Editing by Mark Trevelyan)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.